Search Result

Isoforms Recommended:	Akt1 Akt1

Results for "

AKT1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (79) AMPK (3) Apoptosis (18) Autophagy (11) Bacterial (2) Bcr-Abl (1) CaMK (1) Caspase (2) CDK (2) Discoidin Domain Receptor (1) EGFR (1) FXR (1) HPV (1) HSP (2) Insulin Receptor (2) JNK (1) MDM-2/p53 (2) Microtubule/Tubulin (1) mTOR (3) Organoid (6) Parasite (2) PDK-1 (3) Phosphatase (1) PI3K (3) PKA (6) PKC (4) PPAR (1) PROTAC Linkers (1) PROTACs (7) PTEN (3) Ras (1) Ribosomal S6 Kinase (RSK) (6) ROCK (5) Ser/Thr Protease (2) SGK (2) Small Interfering RNA (siRNA) (4) SphK (1) STAT (1) VEGFR (1)
By Research Areas:	Cancer (79) Endocrinology (2) Infection (5) Inflammation/Immunology (7) Metabolic Disease (9) Neurological Disease (2)
Click Chemistry:	PROTAC Synthesis (1) Alkynes (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (1) Mouse Pre-designed siRNA Sets (1) Human Pre-designed siRNA Sets (2) siRNAs (4)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Recombinant Proteins

Antibodies

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-146459

Akt1-IN-1	Akt	Cancer
Akt1-IN-1 (compound 5b) is a potent and selective *Akt1* inhibitor with an IC₅₀ value of 18.79 nM in MIA Paca-2 cells. Akt1-IN-1 does not exhibit obvious teratogenicity, hepatotoxicity and cardiotoxicity (No Observed Adverse Effect Level > 100 µM). Akt1-IN-1 can be used for researching anticancer ^[1].

HY-RS00544

Akt1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Akt	Others
Akt1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Akt1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Akt1 Rat Pre-designed siRNA Set A Akt1 Rat Pre-designed siRNA Set A

HY-RS00542

AKT1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Akt	Others
AKT1 Human Pre-designed siRNA Set A contains three designed siRNAs for AKT1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

AKT1 Human Pre-designed siRNA Set A AKT1 Human Pre-designed siRNA Set A

HY-RS00543

Akt1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) Akt	Others
Akt1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Akt1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Akt1 Mouse Pre-designed siRNA Set A Akt1 Mouse Pre-designed siRNA Set A

HY-173155

AKT1-IN-9	Akt	Cancer
AKT1-IN-9 (4) is a selective mutant *AKT1(E17K)* inhibitor, with EC₅₀ values of 9 nM and 995 nM in LAPC4-CR and SkBr3 cells, respectively ^[1].

HY-161438

Akt1-IN-3	Akt	Cancer
Akt1-IN-3 (Compd 7) is an inhibitor of *AKT1. Akt1-IN-3 inhibits AKT1- E17K with IC₅₀* < 15 nM ^[1].

HY-163577

Akt1-IN-5	Akt	Cancer
Akt1-IN-5 (Compound 115) is an *Akt1* inhibitor (IC₅₀: <15 nM) ^[1]

HY-163579

Akt1-IN-7	Akt	Cancer
Akt1-IN-7 (Compound 370) is an *Akt1* inhibitor (IC₅₀: <15 nM) ^[1].

HY-163578

Akt1-IN-6	Akt	Cancer
Akt1-IN-6 (Compound 273) is an *Akt1* inhibitor (IC₅₀: <15 nM) ^[1]

HY-161439

Akt1-IN-4	Akt	Cancer
Akt1-IN-4 (Compound 62) is an *AKT1-E17K* inhibitor with an IC₅₀ value of less than 15 nM ^[1].

HY-148868A

Akt1&PKA-IN-2	Akt CDK	Cancer
Akt1&PKA-IN-2 ((R)-29) is an inhibitor of *PKB/AKT* with cyclin-dependent kinase 2 (CDK2) selectivity. Akt1&PKA-IN-2 inhibits AKT1, PKAa and CDK2 ^a with IC₅₀ values of 0.007 µM, 0.01 µM and 0.69 µM, respectively ^[1].

HY-129119

Akt1/Akt2-IN-2	Akt Caspase	Cancer
Akt1/Akt2-IN-2 (compound 7) is an allosteric dual *Akt1* and *Akt2* inhibitor (IC₅₀=138 nM and 212 nM, respectively). Akt1/Akt2-IN-2 increases activity of caspase-3, and inhibits viability of a number of tumor cells ^[1].

HY-50862

Akt1/Akt2-IN-1 1 Publications Verification	Akt	Cancer
Akt1/Akt2-IN-1 (Compound 17) is an allosteric inhibitor of *Akt1* (IC₅₀=3.5 nM) and *Akt2* (IC₅₀=42 nM), with potent and balanced activity ^[1].

HY-148868

Akt1&PKA-IN-1	Akt PKA CDK	Others
Akt1&PKA-IN-1 is a potent dual *Akt/PKA* inhibitor with IC₅₀ values of 0.03 , 0.11 μM, and 9.8 μM for PKAa, Akt, and CDK2, respectively. Akt1&PKA-IN-1 is selective for cyclin-dependent kinase 2 (CDK2) ^[1].

HY-16032

Akt1-IN-2	Akt	Cancer
AKT-I-1 is a selective inhibitor of *Akt1, with an IC₅₀* of 4.6 µM ^[1].

HY-RS00545

AKT1S1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
AKT1S1 Human Pre-designed siRNA Set A contains three designed siRNAs for AKT1S1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

AKT1S1 Human Pre-designed siRNA Set A AKT1S1 Human Pre-designed siRNA Set A

HY-154960

*Tubulin/AKT1-IN-1*	Akt Apoptosis Microtubule/Tubulin	Cancer
Tubulin/AKT1-IN-1 (Compound D1-1) is an inhibitor of tubulin polymerization and *AKT* pathway activation. Tubulin/AKT1-IN-1 significantly inhibits the proliferation and metastasis of H1975 cells and slightly induced their apoptosis and can be used for non-small-cell lung cancer (NSCLC) research ^[1].

HY-169960

2DII	mTOR	Cancer
2DII is a potent and selective mTORC2 inhibitor. 2DII selectively binds mSin1 PH domain and decreases the expression of AKT1 phosphorylation ^[1].

HY-19982

AKT-IN-6	Akt	Cancer
AKT-IN-6 (Example 13) is a potent Akt inhibitor. AKT-IN-6 inhibits Akt1, Akt2 and Akt3 with IC₅₀s < 500nM, respectively. (patent WO2013056015A1).

HY-W750451

Reptoside	Akt	Cancer
Reptoside, an iridoid glucoside, is a DNA damaging active agent. Reptoside has strong interactions with Trp352 and Tyr335 in *AKT1* ^[1].

HY-19719

Miransertib 10+ Cited Publications ARQ-092	Akt Parasite	Infection Cancer
Miransertib (ARQ-092) is a potent, orally active, selective and allosteric *Akt* inhibitor with IC₅₀s of 2.7 nM, 14 nM and 8.1 nM for *Akt1, Akt2, Akt3, respectively. Miransertib is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research ^[1]. Miransertib is effective against Leishmania* .

HY-19719A

Miransertib hydrochloride 10+ Cited Publications ARQ-092 hydrochloride	Akt Parasite	Infection Cancer
Miransertib hydrochloride (ARQ-092 hydrochloride) is a potent, orally active, selective and allosteric *Akt* inhibitor with IC₅₀s of 2.7 nM, 14 nM and 8.1 nM for *Akt1, Akt2, Akt3, respectively. Miransertib hydrochloride is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research ^[1]. Miransertib hydrochloride is effective against Leishmania* .

HY-153640

AKT-IN-14	Akt	Cancer
AKT-IN-14 (Example 2) is a potent AKTinhibitor with the IC₅₀ values of <0.01 nM, 1.06 nM and 0.66 nM for AKT1, AKT2, AKT3, respectively. AKT-IN-14 can be used in cancer research ^[1].

HY-143611

AKT-IN-8	Akt	Cancer
AKT-IN-8 is a potent *AKT* inhibitor with IC₅₀s of 4.46, 2.44, and 9.47 nM for AKT1, AKT2, and AKT3, respectively ^[1].

HY-153640A

AKT-IN-14 free base	Akt	Cancer
AKT-IN-14 (Example 2) free baseis a potent AKTinhibitor with the IC₅₀ values of <0.01 nM, 1.06 nM and 0.66 nM for AKT1, AKT2, AKT3, respectively. AKT-IN-14 free basecan be used in cancer research ^[1].

HY-137458A

Vevorisertib trihydrochloride ARQ 751 trihydrochloride	Akt	Cancer
Vevorisertib (ARQ 751) trihydrochloride is a selective, allosteric, pan-AKT and AKT1-E17K mutant inhibitors. Vevorisertib trihydrochloride potently inhibit phosphorylation of AKT. Vevorisertib trihydrochloride has Kd values of 1.2 nM and 8.6 nM for AKT1 and AKT1-E17K, respectively. Vevorisertib trihydrochloride has IC₅₀ values of 0.55, 0.81, and 1.3 nM for AKT1, AKT2, and AKT3, respectively. Vevorisertib trihydrochloride can be used for the research of cancer ^[1].

HY-100018

BAY1125976 1 Publications Verification	Akt	Cancer
BAY1125976 is a selective allosteric *Akt1/Akt2* inhibitor; inhibits Akt1 and Akt2 activity with IC₅₀ values of 5.2 nM and 18 nM at 10 μM ATP, respectively.

HY-123390

DB07107	Bcr-Abl Akt	Cancer
DB07107 is a potent agent resistant T315I mutant Bcr-Abl tyrosine kinase inhibitor. DB07107 is also a potent *Akt1* inhibitor with an IC₅₀ value of 360 nM ^[1] .

HY-W013816

Dipentyl phthalate	AMPK Akt	Metabolic Disease
Dipentyl phthalate is an endocrine-disrupting phthalate plasticizer. Dipentyl phthalate increases AMPK phosphorylation and decreases AKT1 phosphorylation and SIRT1 levels. Dipentyl phthalate reduces adrenocorticotropic hormone levels. Dipentyl phthalate is a testicular toxicant ^[1].

HY-13254A

A-674563 hydrochloride 4 Publications Verification	Akt	Cancer
A-674563 hydrochloride is a potent and selective *Akt1* inhibitor with K_i of 11 nM.

HY-13254

A-674563 4 Publications Verification	Akt	Cancer
A-674563 is an orally active *Akt1* inhibitor with a K_i of 11 nM.

HY-16666

3CAI 3 Publications Verification	Akt	Cancer
3CAI is a potent and specific *AKT1* and *AKT2* inhibitor.

HY-145281

MS98	PROTACs Akt	Cancer
MS98 is a potent and selective PROTAC AKT degrader. MS98 depletes cellular total *AKT* (T-AKT) with the DC₅₀ value of 78 nM. MS98 binds to AKT1, AKT2, and AKT3 with K_ds of 4 nM, 140 nM, and 8.1 nM, respectively ^[1].

HY-145282

MS170 1 Publications Verification	PROTACs Akt	Cancer
MS170 is a potent and selective PROTAC AKT degrader. MS170 depletes cellular total *AKT* (T-AKT) with the DC₅₀ value of 32 nM. MS170 binds to AKT1, AKT2, and AKT3 with K_ds of 1.3 nM, 77 nM, and 6.5 nM, respectively ^[1].

HY-162285

Anticancer agent 189	Akt	Cancer
Anticancer agent 189 (compound 4) is an anticancer agent that antagonizes CRC effects by targeting *AKT1* ^[1].

HY-112148

AKT-IN-2	Akt	Cancer
AKT-IN-2 is a potent, selective and orally bioavailable *AKT* inhibitor with an IC₅₀ of 5 nM for *AKT1* ^[1].

HY-W013816R

Dipentyl phthalate (Standard)	AMPK Akt	Metabolic Disease
Dipentyl phthalate (Standard) is the analytical standard of Dipentyl phthalate. This product is intended for research and analytical applications. Dipentyl phthalate is an endocrine-disrupting phthalate plasticizer. Dipentyl phthalate increases AMPK phosphorylation and decreases AKT1 phosphorylation and SIRT1 levels. Dipentyl phthalate reduces adrenocorticotropic hormone levels. Dipentyl phthalate is a testicular toxicant ^[1].

HY-138767

AKT-IN-5	Akt	Cancer
AKT-IN-5 (Example 8) is a *Akt* inhibitor with IC₅₀ values of 450 nM and 400 nM for *Akt1* and *Akt2*, respectively ^[1].

HY-15431

Capivasertib 60+ Cited Publications AZD5363	Akt Autophagy	Cancer
Capivasertib (AZD5363) is an orally active and potent *pan-AKT* kinase inhibitor with IC₅₀ of 3, 7 and 7 nM for *Akt1,Akt2* and *Akt3*, respectively.

HY-15965A

Uprosertib hydrochloride GSK2141795 hydrochloride	Akt	Cancer
Uprosertib hydrochloride (GSK2141795 hydrochloride) is a potent and selective *pan-Akt* inhibitor with IC₅₀ values of 180/328/38 nM for Akt1/Akt2/Akt3, respectively.

HY-15965

Uprosertib 15+ Cited Publications GSK2141795	Akt	Cancer
Uprosertib (GSK2141795) is a potent and selective *pan-Akt* inhibitor with IC₅₀ values of 180/328/38 nM for Akt1/Akt2/Akt3, respectively.

HY-18271

CaMKII-IN-1 5 Publications Verification	CaMK Autophagy	Inflammation/Immunology
CaMKII-IN-1 is a potent and highly selective CaMKII inhibitor with IC50 of 63 nM; significantly high selectivity against CaMKIV, MLCK, p38a, Akt1, and PKC.

HY-151613

MS15	PROTACs Akt	Cancer
MS15 is a potent and selective AKT PROTAC degrader. MS15 inhibits the AKT1, -2, and -3 activities, with IC₅₀ values of 798 nM, 90 nM, and 544 nM, respectively ^[1].

HY-10425

A-443654 10+ Cited Publications	Akt	Cancer
A-443654 is a *pan-Akt* inhibitor and has equal potency against *Akt1, Akt2, or Akt3* within cells (K_i=160 pM) ^[1].

HY-15186A

Ipatasertib dihydrochloride 40+ Cited Publications GDC-0068 dihydrochloride; RG-7440 dihydrochloride	Organoid Akt	Cancer
Ipatasertib dihydrochloride (GDC-0068 dihydrochloride) is a highly selective and ATP-competitive *pan-Akt* inhibitor with IC₅₀s of 5, 18 and 8 nM for *Akt1, Akt2* and *Akt3*, respectively.

HY-151613A

MS15 TFA	PROTACs Akt	Cancer
MS15 TFA is a potent and selective AKT PROTAC degrader. MS15 TFA inhibits the AKT1, -2, and -3 activities, with IC₅₀ values of 798 nM, 90 nM, and 544 nM, respectively ^[1].

HY-15727

Afuresertib 10+ Cited Publications GSK2110183; LAE002	Akt PKC ROCK	Cancer
Afuresertib (GSK2110183) is an orally bioavailable, selective, ATP-competitive and potent pan-Akt kinase inhibitor with K_is of 0.08/2/2.6 nM for Akt1/Akt2/Akt3, respectively ^[1] .

HY-15727A

Afuresertib hydrochloride 10+ Cited Publications GSK2110183 hydrochloride; LAE002 hydrochloride	Akt PKC ROCK	Cancer
Afuresertib hydrochloride (GSK 2110183 hydrochloride) is an orally bioavailable, selective, ATP-competitive and potent pan-Akt kinase inhibitor with K_is of 0.08/2/2.6 nM for Akt1/Akt2/Akt3 respectively ^[1] .

HY-133120

INY-03-041 1 Publications Verification	PROTACs Akt	Cancer
INY-03-041 is a potent, highly selective and PROTAC-based pan-AKT degrader consisting of the ATP-competitive *AKT* inhibitor Ipatasertib (HY-15186) conjugated to Lenalidomide (HY-A0003, Cereblon ligand). INY-03-041 inhibits *AKT1, AKT2* and *AKT3* with IC₅₀s of 2.0, 6.8 and 3.5 nM, respectively ^[1].

HY-N10336

Notoginsenoside R4	VEGFR STAT Akt Ras	Others
Notoginsenoside R4 is a ginsenoside that can be isolated from ginseng roots. In the molecular docking results, Notoginsenoside R4 can target STAT3, AKT1, HRAS, VEGFA and CASP3 ^[1] .

Cat. No.	Product Name

HY-L015

PI3K/Akt/mTOR Compound Library

708 compounds

The PI3K/Akt/mTOR pathway controls many cellular processes that are important for the formation and progression of cancer, including apoptosis, transcription, translation, metabolism, angiogenesis, and cell cycle progression. Every major node of this signaling network is activated in a wide range of human tumors. Mechanisms for the pathway activation include activation of receptor tyrosine kinases (RTKs) upstream of PI3K, mutation or amplification of PIK3CA encoding p110α catalytic subunit of PI3K, mutation or loss of PTEN tumor suppressor gene, and mutation or amplification of Akt1. Once the pathway is activated, signaling through Akt can stimulate a series of substrates including mTOR which is involved in protein synthesis. Thus, inhibition of this pathway is an attractive concept for cancer prevention and/or therapy. Currently some mTOR inhibitors are approved for several indications, and there are several novel PI3K/Akt/mTOR inhibitors in clinical trials.

MCE owns a unique collection of 708 compounds that can be used for PI3K/Akt/mTOR pathway research. PI3K/Akt/mTOR Compound Library also acts as a useful tool for anti-cancer drug discovery.

Cat. No.	Product Name	Target	Research Area

HY-P5910

Azurin p28 peptide	MDM-2/p53 Apoptosis	Cancer
Azurin p28 peptide is a tumor-penetrated antitumor peptide. Azurin p28 peptide redues proteasomal degradation of p53 through formation of a p28: p53 complex. Azurin p28 peptide induces apoptosis or cell cycle arrest. Azurin p28 peptide inhibits p53-positive tumor growths. Azurin p28 peptide shows antiangiogenic effect by inhibiting phosphorylation of VEGFR-2, FAK and Akt .

HY-P10064

Akt Substrate	Peptides	Others
Akt Substrate (Akt/SKG substrate) is a 7 amino acid synthetic peptide suitable as a substrate for *Akt* .

HY-P5910A

Azurin p28 peptide TFA	MDM-2/p53 Apoptosis	Cancer
Azurin p28 peptide TFA is a tumor-penetrated antitumor peptide. Azurin p28 peptide TFA redues proteasomal degradation of p53 through formation of a p28: p53 complex. Azurin p28 peptide TFA induces apoptosis or cell cycle arrest. Azurin p28 peptide TFA inhibits p53-positive tumor growths. Azurin p28 peptide TFA shows antiangiogenic effect by inhibiting phosphorylation of VEGFR-2, FAK and Akt .

Recombinant Proteins Recommended:

AKT Serine/Threonine Kinase 1 (AKT1)

Species:	Human (3)
Tag:	His (2) GST (2)
Source:	Sf9 insect cells (3)

Cat. No.	Compare	Product Name	Species	Source

HY-P74421

	AKT1 Protein, Human (sf9, His) 3 Publications Verification RAC-alpha serine/threonine-protein kinase; PKB; RAC-PK-alpha; AKT1; RAC	Human	Sf9 insect cells
	The AKT1 protein is part of the AKT kinase family and is critical for metabolism, proliferation, survival, growth, and angiogenesis. It phosphorylates more than 100 substrates, coordinates insulin-induced SLC2A4/GLUT4 translocation, affects glucose uptake, and controls glycogen storage through inhibition of GSK3A/B. AKT1 Protein, Human (sf9, His) is the recombinant human-derived AKT1 protein, expressed by Sf9 insect cells , with C-10*His labeled tag.

HY-P702631

	AKT1 Protein, Human (Active, sf9, GST) AKT1; v-AKT murine thymoma viral oncogene homolog 1; RAC-alpha serine/threonine-protein kinase; AKT; PKB; PRKBA; RAC; PKB alpha; RAC-PK-alpha; proto-oncogene c-AKT; protein kinase B alpha; rac protein kinase alpha; PKB-ALPHA; RAC-ALPHA; MGC99656	Human	Sf9 insect cells
	The AKT1 protein is part of the AKT kinase family and is critical for metabolism, proliferation, survival, growth, and angiogenesis. It phosphorylates more than 100 substrates, coordinates insulin-induced SLC2A4/GLUT4 translocation, affects glucose uptake, and controls glycogen storage through inhibition of GSK3A/B. AKT1 Protein, Human (Active, sf9, GST) is the recombinant human-derived AKT1, expressed by Sf9 insect cells , with GST labeled tag. The total length of AKT1 Protein, Human (Active, sf9, GST) is 480 a.a.,

HY-P704088

	AKT1 Protein, Human (S473D, sf9, His, GST) RAC-alpha serine/threonine-protein kinase; PKB; RAC-PK-alpha; AKT1; RAC	Human	Sf9 insect cells

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80007

	AKT1 Antibody (YA834)	WB, IHC-P	Human
	AKT1 Antibody (YA834) is a non-conjugated and Mouse origined monoclonal antibody about 56 kDa, targeting to AKT1. It can be used for WB,ICC,IHC-P,FC assays with tag free, in the background of Human.

HY-P80008

	AKT1 Antibody (YA634) AKT 1; AKT; AKT1; AKT1_HUMAN ; MGC99656; PKB; PKB-ALPHA; PRKBA; Protein Kinase B Alpha ; Proto-oncogene c-AKT; RAC Alpha;	IHC-P, IHC-F, ICC/IF, IP, FC	Human, Mouse
	AKT1 Antibody (YA634) is a non-conjugated and Rabbit origined monoclonal antibody about 56 kDa, targeting to AKT1. It can be used for IHC-P, IP, FC, IHC-Fr, IF-Cell assays with tag free, in the background of Human, Mouse.

HY-P80535

	AKT1/AKT2/AKT3 Antibody (YA635) AKT1,AKT2,AKT3	WB, IHC-F, IHC-P, ICC/IF, IP	Human, Mouse, Rat, Hamster
	AKT Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 56 kDa, targeting to AKT. It can be used for WB,IHC-F,IHC-P,ICC/IF,IP assays with tag free, in the background of Human, Mouse, Rat, Hamster.

HY-P80009

	AKT1/2/3 Antibody (YA633)	WB, ICC/IF, IHC-P, IP, FC	Human, Mouse
	AKT1/2/3 Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 56 kDa, targeting to AKT1/2/3. It can be used for WB,ICC/IF,IHC-P,IP,FC assays with tag free, in the background of Human, Mouse.

HY-P83434

	PRAS40 Antibody (YA3179) AKT1S1; PRAS40; Proline-rich AKT1 substrate 1; 40 kDa proline-rich AKT substrate	WB, IP	Human, Rat
	PRAS40 Antibody (YA3179) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3179), targeting PRAS40, with a predicted molecular weight of 27 kDa (observed band size: 40 kDa). PRAS40 Antibody (YA3179) can be used for WB, IP experiment in human, rat background.

HY-P80276

	*Phospho-AKT1(Ser473) Antibody* AKT 1 antibody; AKT antibody; AKT1 antibody; AKT1_HUMAN antibody; MGC99656 antibody; PKB antibody; PKB-ALPHA antibody; PRKBA antibody; Protein Kinase B Alpha antibody; Protein kinase B antibody; Proto-oncogene c-AKT antibody; RAC Alpha antibody; RAC antibody; RAC-alpha serine/threonine-protein kinase antibody; RAC-PK-alpha antibody;	WB, ICC/IF, IHC-P	Human, Mouse
	Phospho-Akt1(Ser473) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 56 kDa, targeting to Phospho-Akt1(Ser473). It can be used for WB,ICC/IF,IHC-P assays with tag free, in the background of Human, Mouse.

HY-P80788

	*Phospho-AKT1* (Ser473) Antibody** AKT1; PKB; RAC; RAC-alpha serine/threonine-protein kinase; Protein kinase B; PKB; Protein kinase B alpha; PKB alpha; Proto-oncogene c-AKT; RAC-PK-alpha	WB	Human, Mouse, Rat
	Phospho-AKT1 (Ser473) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 56 kDa, targeting to Phospho-AKT (Ser473). It can be used for WB assays with tag free, in the background of Human, Mouse, Rat.

HY-P80789

	*Phospho-AKT* (Thr308) Antibody** AKT1; PKB; RAC; RAC-alpha serine/threonine-protein kinase; Protein kinase B; PKB; Protein kinase B alpha; PKB alpha; Proto-oncogene c-AKT; RAC-PK-alpha	ICC/IF, WB, IHC-F, IHC-P, ELISA	Human, Mouse, Rat
	Phospho-AKT (Thr308) Antibody is a non-conjugated and Rabbit origined polyclonal antibody about 56 kDa, targeting to Phospho-AKT (Thr308). It can be used for ICC/IF,WB,IHC-F,IHC-P,ELISA assays with tag free, in the background of Human, Mouse, Rat.